Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Prologue Medicines

Request full access

Prologue is systematically discovering the therapeutic potential of secreted proteins tuned through millennia of natural evolution to rapidly create powerful new medicines

Cambridge, United StatesFounded 2022Biotech & Life Sciences

About Prologue Medicines

Prologue Medicines is a biotechnology company focused on discovering and developing new therapeutics by exploring the vast and largely untapped viral proteome. The company was founded in 2021 by Flagship Pioneering, a life sciences venture creation firm. It officially launched in May 2024 with an initial commitment of $50 million from Flagship.

The company was co-founded by a team of seasoned scientists and entrepreneurs from Flagship Pioneering, including Noubar Afeyan, Lovisa Afzelius, Theonie Anastassiadis, and Hozefa Bandukwala. Noubar Afeyan, the founder and CEO of Flagship Pioneering and co-founder of Moderna, serves as the Chairman of the Strategic Oversight Board. Lovisa Afzelius, a General Partner at Flagship with extensive experience in data-driven drug discovery, leads the company as CEO. The founding team also includes Theonie Anastassiadis as Founding President and Hozefa Bandukwala as Founding Chief Scientific Officer, both of whom bring deep expertise from previous roles at Flagship-backed ventures and major pharmaceutical companies.

Prologue's core business revolves around its proprietary drug discovery platform, DELVE™ (Decoding Evolutionary Logic of Variant Ensembles). This platform utilizes machine learning and high-throughput biology to systematically mine the viral proteome, which is orders of magnitude larger than the human proteome. The central thesis is that viruses have evolved highly specialized proteins that can modulate human physiology with greater potency than human proteins themselves. By identifying and understanding these viral proteins, Prologue aims to develop a new class of programmable medicines. The DELVE platform integrates the largest known database of viral protein structures with data on human proteins and proprietary computational predictions to identify promising therapeutic candidates.

The company's business model is centered on leveraging this platform to build a pipeline of first-in-class drugs. While open to partnerships, its primary focus is on internal drug development. Revenue generation will ultimately depend on the successful clinical development and commercialization of its therapeutic candidates or through strategic collaborations with larger pharmaceutical companies. The initial therapeutic areas of focus for Prologue are immunology, oncology, and metabolic diseases.

Source: Dealroom company data

At a glance

Status
Operational
Employees
20
Open positions
1
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, DT and LS
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing May 2024 $50M $200M Flagship Pioneering ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Prologue Medicines website traffic

Latest recorded traffic for Prologue Medicines is 1.2K monthly website visits, up 106.9% over the last three months.

Latest monthly visits1.2K 3-month web change+106.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Prologue Medicines in the Cambridge ecosystem

Live from Dealroom

The Prologue Medicines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Employees 20 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States94.1%
🇬🇧 United Kingdom5.9%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Prologue Medicines on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Prologue Medicines’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.